Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 May 1.

Published in final edited form as: Clin Cancer Res. 2012 Mar 15;18(9):2668–2678. doi: 10.1158/1078-0432.CCR-12-0261

Table 4.

Pharmacokinetic parameters after intraperitoneal administration of pemetrexed

Dose (mg/m²)	Plasma			IP Fluid
Dose (mg/m²)	C_max (μg/ml)	AUC_{0-24 h} (μg/ml *h)	C_{24 h} (μg/ml)	C_max (μg/ml)	AUC_{0-24 h} (μg/ml *h)	C_{24 h} (μg/ml)
*500*
Subject 006	25.6	301.0	0.119	ND^a	ND	ND
Subject 007	26.5	248.2	0.076	ND	ND	ND
Subject 008	24.0	331.2	1.826	ND	ND	ND
Mean ± SD	25.1 ± 1.3	293.5 ± 42.0	0.674 ± 0.998	ND	ND	ND
*750*
Subject 009	46.8	452.6	0.451	ND	ND	ND
Subject 010	47.0	482.8	0.448	ND	ND	ND
Subject 011	34.3	370.9	0.356	ND	ND	ND
Mean ± SD	39.3 ± 7.3	422.2 ± 57.9	0.418 ± 0.054	ND	ND	ND
*1000*
Subject 012	51.6	722.8	5.42	719.4	9394.1	22.6
Subject 014	31.6	366.6	3.07	ND	ND	22.3
Subject 015	33.0	611.1	33.0	260.3	2430.3	32.7
Mean ± SD	38.7 ± 11.2	566.8 ± 182.1	13.8 ± 16.6	489.8 ± 324.7	5912.2 ± 4924.1	25.9 ± 5.95